The Clinical Observation Of Entecavir Combined With Fuzheng Huayu Capsule In Treating Decompensated Cirrhosis Caused By HBV

Objectives: By comparing the clinical efficacy of Entecavir combined with Fuzheng Huayu capsule and Entecavir alone in treating decompensated cirrhosis caused by HBV,we try to evaluate the scientific and objective clinical efficacy of Entecavir combined with Fuzheng Huayu capsule in treating decompensated cirrhosis caused by HBV,and to improve the reversal rate of liver cirrhosis,and to provide a useful reference for treating decompensated cirrhosis.Methods: 60 cases were enrolled in Ruikang Hospital Affiliated To Guangxi University of Chinese Medicine,and they were divided into treatment group and control group randomly.All of them were diagnosed with hepatitis B liver cirrhosis,which were treated in our hospital during January 2014 to January 2015.The 30 patients in control group were given a simple Entecavir treatment,while the other 30 cases in treatment group were given Entecavir combined with Fuzheng Huayu capsule.The treatment last 48 weeks.Then the clinical symptom score,liver function(ALT?AST),serum markers of liver fibrosis(HA??NP?LN?CIV),HBV DNA,value changes of serum E antigen negative,The portal vein width and the thickness of the spleen were recorded.Results: Compared with before treatment,the clinical symptom score and liver function and serum markers of liver fibrosis of the treatment group and control group were declined when treated for 24 weeks and 48 weeks,while the negative rate of HBV DNA and E antigen were increased.There were significant differences in the comparison group(P <0.05).Compared with the control group,the clinical symptom score and liver function and serum markers of liver fibrosis of the treatment group were better(P<0.05).However,there were no difference when comparing the negative rate of HBV DNA and E antigen of the treatment group and control group(P>0.05).All the patients' portal vein width and the thickness of the spleen were declined when treated for 24 weeks and 48 weeks,and There were significant differences in the comparison group(P <0.05).There wes no significant difference when comparing the portal vein width and the thickness of the spleen in Comparison between groups when treated for 24 weeks(P>0.05).Compared with the control group,the portal vein width and the thickness of the treatment group were lower when treated for 48 weeks(P<0.05).Conclusions: The clinical efficacy of Entecavir combined with Fuzheng Huayu capsule in treating decompensated cirrhosis caused by HBV was good.It do good to patients with liver cirrhosis,and it can improve the clinical efficacy and delay the progression of liver cirrhosis when applied with Antiviral drugs.